Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1929       

   Table of Contents      
REVIEW ARTICLE
Year : 2020  |  Volume : 152  |  Issue : 3  |  Page : 185-226

Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases


Department of Molecular Medicine, Jamia Hamdard Institute of Molecular Medicine, Jamia Hamdard (Deemed-to-be-University), New Delhi, India

Date of Submission03-Apr-2020
Date of Web Publication17-Oct-2020

Correspondence Address:
Dr Surendra K Sharma
Department of Molecular Medicine, Jamia Hamdard Institute of Molecular Medicine, Jamia Hamdard (Deemed-to-be-University), Hamdard Nagar, New Delhi 110 062
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmr.IJMR_902_20

Rights and Permissions
   Abstract 

Non-tuberculous mycobacteria (NTM) are ubiquitously present in the environment, but NTM diseases occur infrequently. NTM are generally considered to be less virulent than Mycobacterium tuberculosis, however, these organisms can cause diseases in both immunocompromised and immunocompetent hosts. As compared to tuberculosis, person-to-person transmission does not occur except with M. abscessus NTM species among cystic fibrosis patients. Lung is the most commonly involved organ, and the NTM-pulmonary disease (NTM-PD) occurs frequently in patients with pre-existing lung disease. NTM may also present as localized disease involving extrapulmonary sites such as lymph nodes, skin and soft tissues and rarely bones. Disseminated NTM disease is rare and occurs in individuals with congenital or acquired immune defects such as HIV/AIDS. Rapid molecular tests are now available for confirmation of NTM diagnosis at species and subspecies level. Drug susceptibility testing (DST) is not routinely done except in non-responsive disease due to slowly growing mycobacteria ( M. avium complex, M. kansasii) or infection due to rapidly growing mycobacteria, especially M. abscessus. While the decision to treat the patients with NTM-PD is made carefully, the treatment is given for 12 months after sputum culture conversion. Additional measures include pulmonary rehabilitation and correction of malnutrition. Treatment response in NTM-PD is variable and depends on isolated NTM species and severity of the underlying PD. Surgery is reserved for patients with localized disease with good pulmonary functions. Future research should focus on the development and validation of non-culture-based rapid diagnostic tests for early diagnosis and discovery of newer drugs with greater efficacy and lesser toxicity than the available ones.

Keywords: Diagnosis - non-tuberculous mycobacteria pulmonary disease - NTM - NTM extrapulmonary disease - treatment


How to cite this article:
Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res 2020;152:185-226

How to cite this URL:
Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res [serial online] 2020 [cited 2020 Oct 31];152:185-226. Available from: https://www.ijmr.org.in/text.asp?2020/152/3/185/298483


   Introduction Top


Non-tuberculous mycobacteria (NTM) are known by several names including environmental mycobacteria, atypical mycobacteria or anonymous mycobacteria, mycobacteria other than Mycobacterium tuberculosis (Mtb) (MOTT) and its close relatives, M. africanum, M. bovis, M. canetti, M. caprae, M. pinnipedii and M. leprae[1]. These organisms are ubiquitous in the environment and have been isolated from air, soil, dust, plants, natural and drinking water sources including biofilms, wild animals, milk and food products[2],[3]. NTM are characterized by a thin peptidoglycan layer surrounded by a thick outer lipid-rich coating that enables NTM attachment to rough surfaces and by offering resistance to antibiotics and disinfectants, helping NTM survival in low oxygen and carbon concentrations and in other adverse conditions[4]. Based on their growth characteristics from the subculture, NTM are divided into rapidly growing mycobacteria (RGM; <7 days) and slowly growing mycobacteria (SGM; ≥7 days)[5][Table 1]. At present, there is no evidence for the latency of NTM[6]. Taxonomy of the genus Mycobacterium includes about 200 species and 13 subspecies[7],[8],[9].
Table 1: Common non-tuberculous mycobacteria (NTM) species causing human diseases

Click here to view


In high tuberculosis (TB)-burden countries, diagnosis of NTM is rarely made because of lack of awareness among healthcare providers about the NTM diseases and poor access to adequate laboratory resources including mycobacterial culture and molecular methods for identification or speciation[10]. In these resource-limited settings, there is a heavy reliance on smear microscopy for the diagnosis of TB, and the diagnosis of NTM is frequently missed and these patients are empirically treated as drug-sensitive and -resistant TB[11].


   Epidemiology Top


NTM disease burden

[Table 2] describes the distribution of various NTM species in the environment[2],[3]. [Table 3] details the major differences between NTM and Mtb[1],[2],[3],[4],[5],[6],[9],[12],[13],[14],[15],[16],[17],[18],[19],[20]. Although recent reports regarding the transmission of M. abscessus and M. massiliense have not proven person-to-person transmission, but these are highly suggestive of indirect transmission among cystic fibrosis (CF) patients[21]. Systematic reporting of NTM diagnosis is not done because the disease is not notifiable to public health authorities in several countries[10]. NTM lung infection rates, defined as individuals with NTM-positive cultures and those with defined NTM pulmonary disease (NTM-PD), increase with age[22] and differ considerably among various countries[23],[24],[25]. Many studies have suggested an increase in the prevalence rates of NTM over the last four decades[22],[25],[26],[27],[28],[29],[30],[31],[32],[33],[34],[35],[36]. The data from the USA suggest that the current prevalence of NTM-positive culture ranges between 1.4 and 6.6/100,000 individuals[26], whereas UK data suggest that NTM-positive culture incidence has increased from 4/100,000 to 6.1/100,000 individuals between 2007 and 2012[35]. A study from Canada has reported a significant increase in the prevalence of NTM-PD from 29.3 cases/100,000 in 1998-2002 to 41.3/100,000 individuals tested in 2006-2010[36]. Several factors that have contributed to this increase in the incidence and prevalence are listed in [Box 1][37],[38]. Published reports on rate of NTM isolation from several countries are summarized in [Table 4][22],[29],[30],[39],[40],[41],[42],[43],[44],[45],[46],[47],[48],[49],[50],[51],[52],[53],[54],[55],[56],[57],[58],[59],[60],[61],[62],[63].
Table 2: Environmental niches of non-tuberculous mycobacteria (NTM)

Click here to view
Table 3: Differences between non-tuberculous mycobacteria (NTM) and Mycobacterium tuberculosis (Mtb)

Click here to view
Table 4: Global prevalence of pulmonary non-tuberculous mycobacteria (NTM) isolation and NTM disease

Click here to view



Details of 13 Indian studies published between 1985 and 2019 are summarized in [Table 5][59],[60],[61],[62],[63],[64],[65],[66],[67],[68],[69],[70],[71]. Most of these studies have reported NTM isolation rates from laboratories without describing clinical features and treatment details. Two studies were done exclusively on extrapulmonary specimens and 11 on both pulmonary and extrapulmonary specimens. NTM isolation prevalence varied between 0.38 and 23.7 per cent. Six of these 13 studies reported NTM prevalence ≤1 per cent among TB suspects. Almost all except one study have not provided treatment outcomes. Most of the studies (11/13) were hospital based and had selection bias. A large community-based study from south India conducted at four sites in the pre-HIV era has reported NTM isolation prevalence between 4.5 and 8.6 per cent in the sputum specimens. This variable NTM prevalence can be attributed to the following factors: (i) differences in study designs, (ii) standard American Thoracic Society (ATS) (2007)[17] and British Thoracic Society (BTS) (2017)[1] guidelines criteria were not followed in most of these studies, (iii) only laboratory-related NTM culture data have been reported, and (iv) most of the studies have not provided clinical details and treatment outcomes. Of the 13 studies, only two[61],[71] followed ATS guidelines (2007)[17] and one of these reported treatment outcomes[61]. Future studies should report about extrapulmonary NTM diseases in addition to clinical details including treatment outcomes of various NTM diseases.
Table 5: Summary of Indian studies on non-tuberculous mycobacteria (NTM)

Click here to view


Risk factors for NTM disease

Risk factors for NTM diseases vary according to the clinical type of NTM disease[72],[73],[74]. Various risk factors for NTM-PD are described in [Box 2]A[72],[73],[74]. Pre-existent lung disease is mostly present in these patients. In the absence of obvious structural lung disease, patients may have quantitatively impaired ciliary function or may be heterozygous for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations[75],[76]. Extrapulmonary NTM disease can occur due to breaches in skin or soft tissues or due to several nosocomial factors, which are detailed in [Box 2]B[72],[73],[74]. Disseminated NTM disease generally occurs in patients having primary or acquired immunodeficiency conditions. Certain environmental and organism-related factors such as water sources and reservoirs, and NTM growth characteristics in different climatic conditions, have also been reported as risk factors [Box 2]B[72],[73],[74]. In addition, habits, hobbies and profession of an individual may also increase the risk of having NTM disease[74].



Immunopathogenesis of NTM disease

In addition to lung, the most common organ involved affected by NTM, localized and disseminated NTM infections can occur[73]. Patients with disseminated NTM infections (defined as involvement of two or more non-contiguous body organs) usually have underlying generalized immune defect such as HIV/AIDS, and 2-8 per cent of these patients may have concurrent pulmonary involvement[77]. Identification of the underlying immune defect is crucial for early diagnosis, treatment and prevention. Patients with NTM disease and underlying primary immunodeficiencies typically present in their childhood or adulthood, whereas those with acquired immunodeficiencies can present at any age [Table 6][73].
Table 6: Primary and acquired immune deficiencies associated with disseminated non-tuberculous mycobacterial (NTM) infection

Click here to view


Antimycobacterial cell-mediated immunity requires a close interaction between myeloid and lymphoid cells [Figure 1][73]. Mononuclear phagocytes after engulfing mycobacteria secrete interleukin-12 (IL-12) which, in turn, stimulates T cells and NK (natural killer) cells through the IL-12 receptor (heterodimer of IL12RB1 and IL12RB2). A complex cascade is triggered by IL-12 receptors via TYK2 (tyrosine kinase) and JAK2 (Janus kinase) signals, leading to STAT-4 (signal transducer and activator of transcription) phosphorylation, homodimerization and nuclear translocation to induce interferon-gamma (IFN-γ) secretion [Figure 1]. IFN-γ binds to its receptor IFNG receptor (IFNGR) (heterodimer of IFNGR1 and IFNGR2) and leads to phosphorylation of JAK2, JAK1 and STAT1 and phosphorylated STAT1 (pSTAT1) homodimerisation. The pSTAT1 homodimer [IFN-γ activators (GAF)] binds to IFN-γ activation sequence which upregulates IFN-γ responsive gene transcription. This cascade leads to activation and differentiation of macrophages. As a result, upregulation of IL-12 and tumour necrosis factor-α (TNF-α) secretions facilitates granuloma formation. After these events, macrophages can kill intracellular mycobacteria being assisted by maturation of mycobacterial phagosome, nutrition deprivation and induction of autophagy, exposure to antimicrobial peptides and reactive oxygen species. The nuclear factor (NF) κB essential modulator-mediated pathway and oxidative burst from macrophages are also important to fight against NTM infection[73]. Genetic defects in any of these immune factors may disturb the cascade of protection against mycobacterial infection and may lead to disseminated NTM disease[73]. These immune defects have been summarized in [Table 6][73].
Figure 1: Host defence mechanisms against non-tuberculous mycobacteria (NTM). Defects leading to disseminated NTM infection are shown in red. ISG15, interferon-stimulated gene 15; IFNGR, interferon-gamma receptor; TYK, tyrosine kinase; JAK, Janus kinase; STAT, signal transducer and activator of transcription; IRF, interferon regulatory factor; GATA, transcription factor implicated in early haemopoietic, lymphatic, and vascular development; NEMO, nuclear factor kappa-light-chain-enhancer of activated B cells essential modulator; IL, interleukin; TNF, tumour necrosis factor; TLR, toll-like receptors. Source: Reproduced with permission from Ref. 73.

Click here to view



   Clinical manifestations Top


The clinical manifestations of NTM disease are similar to those of TB and may pose a diagnostic challenge even to an experienced clinician. NTM disease is classified into four clinical types: (i) chronic PD, (ii) lymphadenopathy, (iii) skin and soft tissues, rarely, bones and joints, and (iv) disseminated disease[73].

Chronic pulmonary disease (PD)

The ATS and Infectious Disease Society of America (IDSA), 2007[17], and BTS, 2017[1], ATS/ERS/ESCMID/IDSA[18] have published guidelines to standardize the diagnosis and treatment of NTM diseases. While evaluating NTM suspects, the following criteria should be followed: (i) pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or high-resolution computed tomography (CT) scan that shows multifocal bronchiectasis with multiple, small nodules; (ii) positive culture results from at least two separate expectorated sputum samples [if the results from the initial sputum samples are non-diagnostic, consider repeat sputum acid-fast bacilli (AFB) smear and culture]; single-positive NTM culture from CT-directed bronchoalveolar lavage or bronchial washing specimen from the affected lung segment of NTM suspect who cannot expectorate sputum or whose sputum is consistently culture-negative; and (iii) other disorders such as TB and fungal infections must be excluded[1],[17].

Patterns of NTM-PD: Chronic PD is the most common form of NTM disease. Three patterns of pulmonary involvement have been described[17]: (i) fibro-cavitary type, which usually occurs in the upper lobe with a history of smoking in an older male patient with pre-existent lung disease such as chronic obstructive pulmonary disease (COPD), bronchiectasis and CF [Figure 2]; (ii) nodular/bronchiectatic type of pattern occurring in post-menopausal, non-smoking females, predominantly having right middle lobe and left lingular bronchiectasis with a few lung nodules. This syndrome was described after the main character in Oscar Wilde's eponymous play as 'Lady Windermere syndrome'[78], and was believed to occur from voluntary cough suppression[79], however, subsequently, this hypothesis was discarded[80]. Other features include mitral valve prolapse, scoliosis and pectus excavatum; high prevalence of gastro-oesophageal reflux disease (GERD) (26-44%)[81],[82]; increased adiponectin; decreased leptin and estrogen levels and abnormalities in fibrillin gene. Presence of all these features increases the susceptibility of these females to MAC infections[83]; and (iii) hypersensitivity pneumonitis-like NTM PD or 'hot tub lung' occurring due to exposure to aerosols from indoor hot tub. Various risk factors for NTM-PD are listed in [Box 2]A.
Figure 2. (A) Chest radiograph in a 62 yr old female with asthma, allergic bronchopulmonary aspergillosis and bronchiectasis. Mycobacterium simiae was isolated repeatedly from the sputum. (B) High-resolution computed tomography chest (axial section) showing bilateral bronchiectasis in the right middle lobe, lingula and lower lobes.

Click here to view


NTM species and NTM-PD: Because of variable virulence, it is important to identify NTM species and M. abscessus subspecies for the management of NTM-PD. It has been reported that only 25-60 per cent of patients with positive respiratory specimen fulfil clinical, radiographic and microbiological criteria of NTM-PD[84]. Patients in whom M. kansasii and M. malmoense are isolated from respiratory specimens frequently meet clinical disease criteria, as these NTM isolates are clinically highly relevant, whereas 40-60 per cent with MAC, M. abscessus and M. xenopi and <20 per cent of patients with M. chelonae and M. fortuitum meet clinical disease criteria[44],[85],[86],[87],[88],[89].

The potential to produce specific clinical type of lung disease also varies among NTM species. While M. kansasii, M. xenopi and M. malmoense commonly cause fibro-cavitary disease but rarely nodular-bronchiectatic disease[17],[44],[90],[91], MAC and M. abscessus cause both types of NTM-PDs and MAC and M. immunogenum cause hypersensitivity pneumonitis-like NTM-PD[17].

MAC is the most common NTM isolated from respiratory secretions in patients with NTM-PD. While a single strain of MAC species is repeatedly isolated in the cavitary type, several strains of MAC species may occur simultaneously or the strain may change sequentially in nodular-bronchiectatic type[92],[93]. Relapse versus new re-infection of MAC infection after treatment completion can be differentiated by MAC genotyping[94].

According to one study from the USA, while tap water was the source of M. avium infection, soil was the source of M. intracellulare infection[94]. It has been suggested that patients with M. intracellulare lung disease present at a later stage with adverse prognosis than patients with M. avium lung disease, and M. chimaera is less virulent than M. avium and M. intracellulare[95],[96]. Significant geographic variation exists in the distribution of NTM species in the USA; where M. avium complex was the most common species isolated in the South, M. abscessus/M. chelonae was proportionately higher in the West in one study[97]. MAC species also vary from region to region: while M. avium is dominantly found in South America and Europe, M. intracellulare is found in South Africa and Australia[23]. Recurrence rates in MAC-associated lung disease also differ among MAC species[95].

The second common NTM species also has a geographical variation. While M. abscessus is the second most common cause of NTM-PD in the USA[98], M. kansasii in some European countries including the UK, M. xenopi in some parts of Europe and Canada and M. malmoense in northern Europe are the second most common causes of NTM-PD[99]. M. kansasii, one of the slowly growing NTM, is most virulent[98]. About 80 per cent of NTM-PD due to RGM results from M. abscessus[100]. There are three subspecies of M. abscessus: (i) M. abscessus subsp. abscessus, which is the most common pathogen (45-65%), followed by (ii) M. abscessus subsp. massiliense (20-55%), and (iii) M. abscessus subsp. bolletii (1-18%)[101]. Patients with gastro-oesophageal disease may have NTM-PD due to RGM such as M. fortuitum[17].

Clinical features: Respiratory symptoms and signs in NTM-PD vary depending on the clinical type. In the cavitary type, these may be severe due to the pre-existent underlying lung disease and include shortness of breath, cough with expectoration and haemoptysis, whereas patients with nodular-bronchiectasis have milder respiratory symptoms without pre-existing parenchymal lung disease and nagging cough may be prominent. Constitutional symptoms such as fever, anorexia, progressive fatigue, malaise and weight loss may be present especially in cavitary type of NTM-PD[1],[17]. The clinical and radiographic presentation in M. kansasii PD is similar to Mtb and includes fever, cough with or without haemoptysis and chest pain, and chest X-ray often shows infiltrates and cavitary lesions[17],[102] [Figure 3]. Patients with hypersensitivity pneumonitis-like NTM-PD have subacute onset of respiratory symptoms involving young individuals without pre-existing lung disease and the prognosis is good[17],[103],[104].
Figure 3: Chest radiograph in a 29 yr old female patient with Mycobacterium kansasii- pulmonary disease. (A) Chest X-ray reveals a cavitary lesion in the left lung. (B) Axial section in the high-resolution computed tomography scan demonstrates a cavity in the left lung (white arrow) and tree-in-bud appearance in the right lung (white circle).

Click here to view


Lymphadenitis

In low TB-burden countries, single-site lymphadenitis is the most common manifestation of NTM infection in younger children[74],[105]. Solitary lymph node is usually localized to the submandibular or cervical region and rarely, can also involve other groups either singly or multiple such as axillary, inguinal region in the disseminated NTM disease in severely immunocompromised individuals[106]. The lymph node enlargement usually starts as a painless swelling and later in the advanced stage, the swelling becomes fluctuant with pus inside, which may later burst out with a sinus formation. Constitutional symptoms such as fever, weight loss and fatigue may be absent. Smear microscopy and culture may be negative because of paucibacillary nature of the disease[17]. Molecular tests may be used to establish the diagnosis. MAC is the most frequently isolated NTM species. There is an inverse relationship of TB incidence and NTM disease and in high TB-burden countries, Mtb is the most frequent cause of lymphadenitis in all ages[106].

Skin, soft tissues and bone NTM infections

Three types of clinical presentations have been described: (i) Buruli ulcer (predominantly occurring in Uganda) or Bairnsdale ulcer disease (predominantly occurring in Australia), certain regional pockets in Latin America and China: it is a severe cutaneous disease due to M. ulcerans which progresses from nodular cutaneous lesions into large painless ulcers[107]. These organisms produce a toxin, mycolactone, which produces damage to the skin[108]. Early diagnosis and treatment is essential to minimize morbidity and costs and prevent long-term disability[109]; (ii) infection due to M. marinum is also known as fish-tank granuloma (previously known as swimming pool granuloma) and the infection can be acquired from swimming pools, cleaning of fish tanks or any other fish- or water-related activity[110]. Organisms usually gain access through skin cuts or abrasions[111]. It starts as a single papulonodular, verrucous or ulcerated granulomatous lesion over the hand and forearm that progresses to form multiple skin lesions in a sporotrichoid pattern - appearance which is similar to skin lesions due to Sporothrix schenckii and rarely, the underlying bone involvement occurs[112]; and (iii) localized skin and soft-tissue infections occurring due to RGM (M. abscessus, M. fortuitum and M. chelonae) at wound or injection sites[113],[114],[115][Figure 4] and [Figure 5] and slowly growing mycobacteria in both immunocompromised and immunocompetent individuals[115],[116]. These organisms gain access through skin breaks following trauma and surgical procedures, following the use of surgical instruments without autoclaving, during cosmetic surgery, pedicure and manicure procedures in beauty salons, surgical procedures involving placement of various implants, in mesh used for hernial site repair [Figure 6], tattooing procedures following inoculation of contaminated ink containing M. haemophilum, intravenous punctures and lines, abscesses due to intramuscular injections through contaminated needles and use of tap water for skin cleaning[112],[113].
Figure 4: (A) A 35 yr old female presented with discharge from the right nipple, Mycobacterium abscessus was isolated from the pus on several occasions prior to treatment. (B) Computed tomography (CT)-chest showing enhancement of the margin of the abscess (black arrow) with intravenous contrast. Source: Reproduced with permission from Ref. 61.

Click here to view
Figure 5: (A) Clinical photograph of a 30 yr old male, showing right-sided post-injection gluteal abscess (black arrow) in a patient with NTM infection. (B) Transaxial fused[18]F-fluorodeoxyglucosepositron emission tomography-computed tomography ([18]F-FDG-PET-CT) image of the same patient, at the level of acetabulum showing FDG accumulation in the subcutaneous thickening and stranding (arrow) involving the underlying right gluteus muscle superficially in right gluteal region. Source: Reproduced with permission from Ref. 61.

Click here to view
Figure 6: Clinical photograph of a 35 yr old male, showing discharging sinus (white arrow) in the abdominal wall in a patient infected with Mycobacterium abscessus following hernia repair with mesh. Source: Reproduced with permission from Ref. 61.

Click here to view


Disseminated NTM disease

Disseminated NTM disease due to MAC is frequent in HIV/AIDS especially in patients with CD4+ lymphocyte count <50 cells/μl. Isolated pulmonary involvement is rare in HIV/AIDS[117]. Pulmonary involvement occurs in 2.5-8 per cent of patients with disseminated MAC[77]. The portal of entry in these patients is believed to be through bowel[118],[119],[120] and occasionally through lungs with subsequent haematogenous dissemination. MAC (predominantly M. avium) is the most common NTM species isolated in these patients[17]. These patients typically present with insidious onset of constitutional symptoms comprising fever with night sweats, weight loss, abdominal pain, diarrhoea and malaise[17]. They may have anaemia, hepatosplenomegaly and lymphadenopathy[17]. Somehow, disseminated NTM infections due to rapidly growing NTM (M. abscessus and M. fortuitum) are rare in HIV/AIDS patients[121]. Besides M. avium, less common NTM species such as M. genavense and M. simiae can also cause disseminated NTM disease in HIV/AIDS patients[17].

M. kansasii can cause pulmonary involvement in HIV/AIDS patients at higher CD4+ counts, and its isolation should always be considered a potential pathogen[17],[122]. Pulmonary involvement can also occur in other immunocompromised populations such as organ transplantation (6.5%)[123], bone marrow (2.9%)[124] and rarely liver and kidney transplantation. CF patients undergoing lung transplantation may develop life-threatening infection with M. abscessus[124]. Disseminated NTM infections can also occur in a few other rare settings [Figure 7]A, [Figure 7]B, [Figure 7]C, [Figure 7]D, [Figure 7]E, [Figure 7]F, [Figure 7]G which will require appropriate investigations. These have been listed in [Box 2]B[73]. NTM, especially M. abscessus [Figure 7] and M. fortuitum, may infect deep indwelling lines[17],[122]. Anti-tumour necrosis factor-α agents (infliximab, etanercept and adalimumab) used to treat several diseases such as rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease can predispose to both TB and NTM diseases[125]. A good response to rituximab in disseminated MAC patients with interferon-gamma autoantibodies has also been reported[126],[127].
Figure 7: The patient, a 14 yr old male, had disseminated Mycobacterium intracellulare infection; no immune defect could be detected. He was successfully treated. (A) The magnetic resonance imaging scan shows osteomyelitis of foot bone (black arrow). (B) Black arrow shows healing of cutaneous lesion by keloid formation. (C) Upper part of thigh shows another healed skin lesion (black arrow). (D and E) Hypodense lesions in the spleen (white open circles) and peri-splenic abscess (white arrows). (F) Bilateral conglomerate necrotic axillary (extreme-left and -right arrows) and right paratracheal lymph nodes (long and short arrows in the centre of CT image), calcification is also noted in the lymph nodes. (G) Iliopsoas abscess on the right side (white asterisk). Source: Reproduced with permission from Ref. 61.

Click here to view



   Diagnosis Top


Criteria for the diagnosis of NTM disease

Healthcare providers should carefully assess causality association of the isolated NTM species with patient's symptoms and signs. Approximately, one-third of NTM species are potentially pathogenic for humans[128]. Some of the common pathogenic NTM species are listed in [Table 7][2],[3],[10],[129]. It is possible that an individual with a particular NTM isolate may not have an active disease or the isolate may not be clinically relevant. While evaluating NTM suspects, the following criteria should be followed: (i) pulmonary symptoms, nodular or cavitary opacities on chest radiograph or high-resolution CT scan that shows multifocal bronchiectasis with multiple small nodules; (ii) positive culture results from at least two separate expectorated sputum samples (if the results from the initial sputum samples are non-diagnostic, consider repeat sputum AFB smear and culture; single-positive NTM culture from CT-directed bronchoalveolar lavage or bronchial washing specimen from the affected lung segment of NTM suspect who cannot expectorate sputum or whose sputum is consistently culture negative); and (iii) other disorders such as TB and fungal infections must be excluded[1],[17].
Table 7: Clinically relevant non-tuberculous mycobacteria species

Click here to view


Differential diagnosis

Because of similar clinical features and radiographic appearances, diseases such as TB, recurrent pulmonary aspirations, pneumonitis, bronchiectasis, histoplasmosis, aspergillosis and lung cancer should be considered in the differential diagnosis and should be appropriately ruled out. In the laboratory, the presence of Pseudomonas aeruginosa, Staphylococcus aureus, Nocardia and Aspergillus in the specimens must be carefully tested[17]. It is important to consider the differential diagnosis of Sporothrix schenckii infection in patients suspected to have skin and soft-tissue NTM disease due to M. marinum[113].

Specimen collection, transportation and processing

A proper sample collection is crucial to establish a correct laboratory diagnosis of NTM disease. In case of NTM-PD patients, during collection of sputum, environmental and personal contamination should be avoided. To differentiate NTM-PD from occasional presence of NTM in tracheobronchial tract, at least 3 sputum specimens should be tested on separate occasions[18]. Sampling from extrapulmonary specimens should be obtained directly from the lesion or organ concerned[130]. Further, instruments used for sampling should be devoid of any contamination, especially in hospital settings. Storage and transportation of specimens should be done carefully[130]. Once the specimen reaches the laboratory, the process of decontamination should be done in fully sterilized set-up. As NTM are resistant to most of the common disinfectants, careful selection of disinfectants is necessary[130]. Various precautions for sample collection, transportation and laboratory processing are listed in [Box 3][130].



Laboratory diagnosis of NTM disease

[Figure 8] illustrates various steps for NTM isolation and identification in the laboratory. Initially, the specimens are simultaneously subjected to AFB (Ziehl-Neelsen or fluorochrome) staining and GeneXpert for Mtb detection. Samples that are positive on AFB staining and negative on GeneXpert are considered NTM suspects, and the culture for such specimens should be done. Most of the NTM are cultivable in Lowenstein-Jensen, Middle-brook and Dubos Broth and Agar. A novel agar-based medium, RGM medium, has been specifically developed for the isolation of rapidly growing NTM. It provides an alternative method for the recovery of NTM from respiratory specimens, particularly from CF patients, by offering a simple and rapid method for specimen processing[131]. For some NTM species, additional supplements (haemin for M. haemophilum and mycobactin J for M. paratuberculosis and M. genavense)[130] are added in the culture medium for optimal growth. Incubation temperatures of 36±2°C for SGM and 28±2°C for RGM have been recommended[18]. Appropriate adjustments in the incubation temperature (M. xenopi: 42-45°C, M. ulcerans and M. marinum: 30°C) may be done for a few NTM species[18],[130]. Some NTM species such as M. tilburgii which are not cultivable need to be tested directly from the specimen using molecular methods[132]. In patients with a high suspicion of NTM-PD but negative cultures, reassessment of decontamination procedures, use of supplemented media and molecular methods may be helpful[18]. Culture isolates of NTM-suspected specimens should be tested with Mtb-specific tests such as MPT64 antigen immunochromatographic test or GeneXpert, and if found negative, then it is likely to be NTM and thereafter its species identification should be done.
Figure 8: Diagnostic algorithm for detection of NTM disease.*According to Ref. 16, consecutive three sputum samples are obtained, positive results from at least two separate expectorated sputum samples confirms the diagnosis.While sputum collection, the patient should not rinse mouth with municipal or untreated water. Spontaneous sputum should be collected or sputum should be induced if no sputum is produced by patient.Whole genome sequencing (NGS) and multi-locus targeted gene sequencing of gene such as 16S rRNA, hsp 65, rpoB, 16S-23S rRNA internal transcribed region (ITS), gyrB, dan A, rec A and sec A. HRCT, high-resolution computed tomography; CSF, cerebrospinal fluid; ICA, immunochromatographic assay; CBNAAT, cartridge based nucleic acid amplification test; L-J, Lowenstein-Jensen media, HPLC: high-performance liquid chromatography, SGM, slowly growing mycobacteria; RGM, rapidly growing mycobacteria; DST, drug susceptibility testing; LPA, line probe assay; PNB: para-nitro benzoic acid; PCR/PRA, polymerase chain reaction/restriction endonuclease assay; MAC, Mycobacterium avium complex; MALDI-TOF MS, matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Click here to view


Earlier, several biochemical tests were done for NTM identification[130][Table 8]. These tests were cumbersome and time consuming and are obsolete now. High-performance liquid chromatography (HPLC)-based analysis of mycolic acid was used for NTM identification in the past. This method identifies slowly growing NTM species such as MAC and M. kansasii, but it is less specific in identifying RGM accurately[130],[133]. It also has low discriminatory power to identify closely related SGM and RGM species[130],[133]. These tests have now been replaced by molecular tests for NTM species and subspecies identification. These tests include polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, gene probes and line probe assays (LPA)[130][Table 8]. These molecular tests though identify a limited number of NTM species, but fail to differentiate genetically closely related NTM species[133].
Table 8: Laboratory methods for non-tuberculous mycobacteria (NTM) identification

Click here to view


At present, DNA sequencing is the most accepted method for the identification and characterization of NTM species and subspecies[134],[135]. These techniques include targeted gene sequencing and multi-locus sequence typing (MLST) that involve analysis of conserved genes such as rpoB, hsp65, 16S rRNA and 16S-23S rRNAinternal transcribed spacer (ITS) region[134]. Targeted sequencing of single gene may identify a reasonable number of NTM species but sometimes may not distinguish species having close genetic association. MLST is preferred as multiple conserved genes are sequenced with this technique and on the basis of consensus analysis of different gene sequences, NTM species are identified more accurately[134].

Whole genome sequencing (WGS) is considered the gold standard for NTM species identification and is helpful in understanding the geographical and environmental distribution of NTM species. It is also useful to study healthcare-associated disease outbreaks and transmission[134]. WGS of NTM species can provide information on other characteristics such as virulence and resistance to various antimicrobial agents[135],[136]. However, DNA sequencing is an expensive method and requires expertise[130]. This technique is not available in the routine laboratory set-up for NTM diagnosis in resource-limited countries[130].

Matrix-assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS)-based analysis of conserved proteins is another technique available for NTM species identification[137]. MALDI-TOF-MS is considered the most rapid technique[137] which identifies around 160 NTM species[138]. However, like other techniques, MALDI-TOF-MS also fails to identify closely linked NTM species[130]. Details of various NTM identifications methods[130] are summarized in [Table 8].

Drug susceptibility testing (DST)

DST for NTM is controversial because of discrepancy between in vitro susceptibility and the treatment response[101]. DST should follow the Clinical and Laboratory Standards Institute (CLSI) guidelines[16]. CLSI recommends that phenotypic DST should be performed using broth microdilution method[18]. Both phenotypic and genotypic DST for MAC and M. kansasii are performed for initial and recurrent isolates. Acquired resistance for macrolide in MAC occurs due to point mutations in the 23S rRNA (rrl) gene and for amikacin due to mutations in 16S rRNA (rrs) gene (amikacin resistance is observed in MAC isolates cultured from sputum specimens of patients who were extensively exposed to the drug or related aminoglycosides)[18]. For MAC, DST against macrolides [clarithromycin is used as a class agent; minimum inhibitory concentration (MIC) cut-off: >32 μg/ml] and amikacin (MIC cut-off: >64 μg/ml for parenteral and >128 μg/ml for liposomal amikacin) and, for M. kansasii, DST against rifampicin (MIC >2 μg/ml) and clarithromycin are used (MIC ≥32 μg/ml)[128]. When M. kansasii is resistant against rifampicin, DST for amikacin, ciprofloxacin, doxycycline, linezolid, minocycline, moxifloxacin, rifabutin, and trimethoprim-sulfamethoxazole is recommended[18]. RGM species (and subspecies) show different drug resistance patterns[1], and DST should be selectively done for the following antibiotics: macrolides, amikacin, tobramycin, imipenem, trimethoprim-sulphamethoxazole, doxycycline, minocycline, tigecycline, cefoxitin and linezolid[1],[65]. Information on an active erm (41) gene is important in RGM (esp. in M. abscessus subspecies) as it can lead to inducible resistance to macrolides[1],[17]. In M. abscessus subsp massiliense, the erm (41) gene is nonfunctional owing to a large deletion, thus rendering the strains macrolide susceptible. The erm (41) gene is non-functional in some M.abscessus subsp. abscessus due to presence of C instead of T at the nucleotide 28 (arginine 10 instead of tryptophan 10)[18]. Constitutive resistance to macrolides can occur due to mutation in 23S rRNA gene[1]. [Table 9] describes various conditions of macrolide resistance among M. abscessus subspecies. M. chelonae is resistant to cefoxitin and sensitive to tobramycin[1].
Table 9: Interpretation of extended clarithromycin susceptibility results for Mycobacterium abscessus

Click here to view



   Treatment of NTM disease Top


Principles of treatment

Several guidelines have been published for the management of NTM diseases[1],[17],[18],[19],[139]. While ATS/ IDSA deals with both pulmonary and extrapulmonary NTM diseases, the US Cystic Fibrosis Foundation and European Cystic Fibrosis Society (ECFS) guidelines, 2016[139], include consensus recommendations for the screening, investigation, diagnosis and management of NTM-PD in individuals with CF, and the BTS guidelines (2017)[1] and ATS/ERS/ESCMID/IDSA guideline (2020)[18] deal with NTM-PDs. The treating physician should be well versed with the prevalence of various NTM species in the geographical area of his/her practice[1],[17]. Despite repeated isolation of NTM, laboratory contamination and colonization in the host must be ruled out. As MAC is the most common cause of NTM-PD worldwide, causality association of repeated NTM isolation in the respiratory specimens should be carefully established after reviewing clinical and radiographic features[1],[17]. Subsequently, the underlying predisposing structural lung disease should be identified and its severity should be evaluated. NTM-PD should be stratified into mild to moderate (non-severe) and severe NTM-PD [Box 4] on the basis of patient's systemic signs and symptoms, chest radiographic appearances and microbiologic features (acid-fast smear status, bacillary load, mycobacterial culture, NTM species and subspecies characterization)[1]. The conventional microbiological outcomes are smear status, culture conversion and relapse[1],[140],[141][Box 5].



The decision to start treatment should be made carefully as patients due to MAC remain stable without antibiotic treatment[1],[17]. Early identification of certain clinical, radiographic and microbiological features that are associated with NTM-related progressive PD, is required. These include presence of severe symptoms, low body mass index (BMI) and poor nutritional status (esp. low albumin), lung cavitation, extensive disease, presence of comorbidity, elevated inflammatory markers, and positive AFB smears and isolation of more virulent NTM species[18],[94],[142],[143]. Recent ATS/ERS/ESCMID/IDSA guideline (2020)[18] suggests initiation of treatment rather than watchful waiting, especially in the context of positive AFB sputum smears and/or cavitary lung disease. Whereas, a watchful waiting is preferred in patients with mild signs and symptoms of disease, higher chances of drug intolerance and adverse drug reactions and NTM species less responsive to treatment (e.g.,M. abscessus). In such cases, treatment should be initiated after counselling the patient about potential adverse effects of antimicrobial therapy, the uncertainties surrounding the benefits of antimicrobial therapy, and the possibility for recurrence including reinfection (specifically in nodular-bronchiectatic disease setting). It is also recommended that treatment regimens should be designed by experts in the management of complicated NTM infections[18].

NTM-PD is generally treated with a drug regimen, consisting of 3-4 antibiotics, administered either daily or thrice weekly depending on the severity of disease, patient's tolerance of drugs and occurrence of side effects, and the therapy is continued for at least 12 months following sputum conversion[17],[18]. [Table 10] summarizes the treatment durations of pulmonary and extrapulmonary NTM diseases[144] due to different species.
Table 10: Durations of treatment for different non-tuberculous mycobacteria (NTM) diseases

Click here to view


A significant proportion of patients with NTM-PD discontinues the prescribed treatment because of lengthy duration and occurrence of side effects[145]. The treatment regimens vary depending on the isolation of NTM species, clinical phenotypes and drug susceptibility profiles, leading to varying therapeutic responses. The variable treatment responses are related to several factors such as NTM species (M. avium vs. M. abscessus) and subspecies (M. abscessus subsp. massiliense vs. M. abscessus subsp. abscessus), disease phenotype [fibrocavitary vs. nodular bronchiectatic (NB)] and the treatment regimen (drug treatment regimen with macrolide vs. without macrolide)[146],[147],[148].

NTM-PD due to MAC is treated with a drug regimen comprising rifampicin (or rifabutin in HIV-positive individuals to avoid drug-drug interactions[19]), ethambutol and macrolide (azithromycin or clarithromycin; some patients tolerate azithromycin better)[1],[17]. There is an

in vitro synergy of antimycobacterial action between rifampicin and ethambutol as the latter destabilizes mycobacterial cell wall and facilitates rifampicin entry into the Mycobacteria to its target site, the RNA polymerase[149],[150]. These two drugs also prevent development of macrolide resistance[151]. Neither isoniazid nor moxifloxacin is much active against MAC; clofazimine and amikacin are good alternatives. The BTS guidelines (2017)[1] and ATS/ERS/ESCMID/IDSA guideline (2020)[18] recommend intermittent three times-weekly treatment for non-cavitary (non-severe) MAC-PD due to potential benefits, better treatment adherence and comparable efficacy[1],[152]. As per guidelines, intravenous or nebulized amikacin can be added as the fourth drug for the initial three months in patients with severe or macrolide-resistant MAC-PD[1] [Table 11]. The pooled treatment success rates in MAC-PD in the five systematic reviews ranged from 32 to 65 per cent, and 12 to 16 per cent of the enrolled patients had not completed treatment[153],[154],[155],[156],[157].
Table 11: Suggested antibiotic regimens for adults with Mycobacterium avium complex (MAC)-pulmonary disease

Click here to view


Miwa et al[158] in a preliminary open-label study compared three-drug regimen (clarithromycin, ethambutol and rifampicin) with two-drug regimen (clarithromycin and ethambutol) and demonstrated the rate of sputum culture conversion at 40.6 per cent with three-drug regimen versus 55 per cent with two-drug regimen, suggesting that two-drug regimen was not inferior to three-drug regimen. Further, the incidence of adverse events leading to treatment discontinuation was higher with the three-drug regimen (37.2 vs. 26.6%)[158].

Koh et al[159] evaluated 481 treatment-naïve patients with MAC lung disease who underwent antibiotic treatment for ≥12 months between January 2002 and December 2013. Nearly 58 per cent had non-cavitary NB disease, 17 per cent had cavitary NB disease and 25 per cent had fibrocavitary disease. The treatment outcomes and redevelopment of NTM lung disease after treatment completion differed by the clinical phenotype of MAC lung disease. Cavitary disease was independently associated with unfavourable outcomes. The NB form was an independent risk factor for the redevelopment of NTM lung disease. Of the

29 per cent of favourable outcomes, redevelopment of NTM lung disease occurred with the same MAC species in 55 per cent patients. In patients with recurrent MAC lung disease due to the same species, genotyping revealed that 74 per cent of cases were attributable to reinfection and 26 per cent to relapse[159].

Addition of once-daily administration of amikacin liposome inhalation suspension (ALIS) (supplied in single-use vials delivering 590 mg amikacin to the nebulizer), also known as 'Arikayce' to standard guideline-based therapy (GBT) in adults with refractory MAC lung disease (with amikacin-susceptible MAC lung disease and MAC-positive sputum cultures despite at least six months of stable therapy considered to be macrolide-based multidrug treatment), has been reported[141]. Addition of ALIS to GBT for the treatment of refractory MAC lung disease achieved significantly greater culture conversion by six month than GBT alone. Respiratory adverse events (primarily dysphonia, cough and dyspnoea) were reported more (87.4%) in patients receiving ALIS+GBT than those receiving GBT alone (50%)[141]. Patients with limited and refractory MAC-PD should be considered for lung resection[134].

Patients with clarithromycin-resistant MAC-PD should be treated with rifampicin, ethambutol and isoniazid or a quinolone and intravenous amikacin or nebulized amikacin (if intravenous amikacin is not tolerated or impractical to administer or is contraindicated) for initial three months[1][Table 11]. The treatment of macrolide-resistant (MR) MAC-PD is challenging because of poor sputum culture conversion rates (15-36%) and high mortality rates at two year (9-15%) and five-year (47%)[160],[161]. A recent systematic review and meta-analysis of nine studies reported poor treatment outcomes in MR-MAC-PD with overall 21 per cent sputum culture conversion rate and 10 per cent one-year all-cause mortality with no difference between NB and FC types of MR-MAC-PD[162]. Despite the combination of multiple antibiotics including ALIS and surgical resection, the treatment outcomes of MR-MAC-PD remained poor.

Patients with NTM-PD due to rifampicin-sensitive M. kansasii are treated with a treatment regimen similar to pulmonary TB[1],[17] comprising rifampicin, ethambutol and isoniazid along with pyridoxine for a fixed duration of 12 months instead of 12 months beyond culture conversion[18]. Even one-time isolation of M. kansasii from patient's sputum sample is considered pathogenic and should be treated immediately[18][Table 12]. Because MICs (minimum inhibitory concentrations) of isoniazid are higher as compared to Mtb, therefore, macrolide (clarithromycin or azithromycin) is preferred over isoniazid for the treatment of M. kansasii[163]. Pyrazinamide is not recommended for M. kansasii pulmonary disease as the organismisnaturally resistant to pyrazinamide (a prodrug) due to reduced pyrazinamidase activity preventing conversion of the drug into pyrazinoic acid which is an active bactericidal compound[164]. Cure rates for rifampicin-sensitive M. kansasii have been >98 per cent[17]. [Table 12] describes treatment regimens for rifampicin-sensitive and rifampicin-resistant M. kansasii[1].
Table 12: Suggested antibiotic regimen for adults with Mycobacterium kansasii-pulmonary disease

Click here to view


[Table 13] details the treatment of PD due to M. xenopi. While four-drug regimen (rifampicin, ethambutol, macrolide and moxifloxacin) is used to treat non-severe disease, intravenous amikacin or nebulized amikacin is added to the regimen as a fifth drug for severe disease[1]. In a retrospective matched cohort study comparing M. xenopi PD to MAC-PD, 24-month mortality was higher in M. xenopi-PD with comorbidities, especially COPD. Rifampicin was less frequently used in M. xenopi[165].
Table 13:Suggested antibiotic regimens for adults with Mycobacterium xenopi-pulmonary disease

Click here to view


Treatment response of macrolide-containing regimen in patients with M. malmoense NTM-PD is better than that of MAC or M. xenopi[90]. [Table 14] provides the details of drug regimen. Treatment for other slowly growing NTM can be extrapolated from common NTM species. Isolation of M. simiae is rarely associated with true infection. Limited success is seen in M. simiae infection with rifampicin- and ethambutol-based drug regimen[166], and a combination of amikacin and clofazimine may be used to construct a drug regimen to treat the infection[167].
Table 14: Suggested antibiotic-regimens for adults with Mycobacterium malmoense-pulmonary disease

Click here to view


The treatment details of PD due to M. abscessus are provided in [Table 15], and antibiotic combination is administered according to the DST profile. In patients with M. abscessus, pulmonary disease is caused by strains with inducible and mutational macrolide resistance, a macrolide-based regimen is recommended if the drug is used as an immunomodulator (macrolide is not considered as active drug in multidrug regimen)[18]. A precise identification of subspecies along with information on erm (41) gene is important in M. abscessus infection[1] because of a variable treatment response. The treatment outcomes among the three subspecies of M. abscessus differ due to erm (41) gene and inducible and constitutive resistance to macrolides[1] [Table 16]. About 15 per cent of M. abscessus strains have a T to C mutation at position 28 in erm (41) gene, making them macrolide susceptible[168].
Table 15: Suggested antibiotic regimens for adults with Mycobacterium abscessus-pulmonary disease

Click here to view
Table 16: Drugs used in non-tuberculous mycobacteria (NTM) disease, monitoring and adverse drug reactions

Click here to view


A systematic review and meta-analysis of the studies on the effect of chemotherapy on pulmonary M. abscessus with macrolide-containing regimens reported adverse microbiological outcomes with frequent recurrences according to the subspecies[169]. A good outcome was defined as sustained sputum culture conversion (SSCC) without relapse. Macrolide-containing regimens achieved SSCC in only 34 per cent (77/233) patients with new M. abscessus subsp. abscessus vs. 54 per cent (117/141) in those with M. abscessus subsp. massiliense. In refractory disease, SSCC was achieved in 20 per cent of patients, which was not significantly different across subspecies. The proportion of patients with good outcomes (SSCC rate without relapse) was 23 per cent (52/223) with M. abscessus subsp. abscessus versus 84 per cent (118/141) with M. abscessus subsp. massiliense disease. The pooled sputum culture conversion rate was 20 per cent (95% confidence interval, 7-36%), which on follow up after stopping therapy for

12 months was not significantly different across the mycobacterial species. Overall, disease recurrence in M. abscessus subsp. abscessus-infected patients was 40 per cent versus seven per cent in M. abscessus subsp. massiliense-infected patients. The odds ratio of recurrence in M. abscessus subsp. abscessus-infected versus M. abscessus subsp. massiliense-infected patients was 6.2[169].

In patients with lung infection due to M. fortuitum, the underlying GERD should be carefully evaluated and treated[17],[170]. Surgical excision is the treatment of choice for younger children with cervicofacial lymphadenitis due to NTM[105],[171]. Treatment of the skin disease due to M. marinum depends on the extent of lesions, hence drug regimen comprising rifampicin and ethambutol or ethambutol and clarithromycin is administered for a single small lesion, whereas triple-drug regimen of rifampicin, ethambutol and a macrolide is used for severe disease[172],[173],[174]. Adjunctive surgical debridement is recommended for the underlying bone and joint involvement. Eight-week drug regimens of rifampicin with either clarithromycin or quinolone are administered for the treatment of M. ulcerans skin disease[175],[176]. Disseminated skin and subcutaneous abscesses caused by RGM can be treated with two-drug regimen based on DST results for four months[17] in addition to surgical debridement[177],[178]. For M. fortuitum infection, drug regimen may include a combination of co-trimoxazole, tobramycin, imipenem, doxycycline and fluoroquinolones[17]; M. chelonae infection is treated with two-drug combinations of tobramycin, linezolid, macrolides and imipenem[17],[177],[178]. M. abscessus infections may be treated with a combination of the following antibiotics: amikacin, linezolid, cefoxitin, macrolides and imipenem based on DST results[17],[18]. The utility of macrolides depends on erm (41) gene functional status [Table 4].

Recent recommendations for treating disseminated MAC disease in HIV/AIDS patients are provided in [Box 6][19]. Non-steroidal anti-inflammatory drugs (NSAIDS) may be used in HIV patients experiencing moderate-to-severe symptoms of immune reconstitution inflammatory syndrome (IRIS), and short-term course of corticosteroids for 4-8 wk can be used if symptoms persist.



Inhaled antibiotics for NTM-PD

Similar to TB treatment, drug treatment regimens comprising 3-4 drugs are used for treating NTM-PD for longer periods with high discontinuation rates (9-39%) due to significant side effects[145],[154],[179],[180]. Use of inhaled drugs has demonstrated successful treatment outcomes in bronchial asthma, COPD and Pseudomonas aeruginosa infections in CF patients while achieving higher drug concentrations at the disease site without developing significant systemic side effects at the same time[155]. Similar approach can be considered in NTM-PD to deliver higher drug concentrations to the infected lungs with minimal extrapulmonary exposure to avoid adverse events. Inhaled amikacin along with other oral drugs is already used in patients with severe NTM-PD[1],[180],[181],[182]. Development of inhaled clofazimine suspension for administration via nebulizer device in NTM-PD treatment is in progress[180]. In addition, studies using inhaled recombinant granulocyte-macrophage colony-stimulating factor and exogenous nitric oxide gas are in progress to evaluate their antibacterial effect on M. abscessus[183].

Non-pharmacologic treatment of pulmonary NTM disease

In addition to pharmacological therapy, other non-pharmacological measures can be tried for treating the underlying lung disease[184] These include techniques for mucus clearance such as nebulization using hypertonic saline, aerobic exercises, chest physiotherapy, postural drainage, use of oscillating positive expiratory pressure devices and high-frequency chest wall oscillation. Intake of balanced diet containing adequate calories and proteins to maintain ideal body weight is essential in the management of NTM diseases[185]. Following recovery, patients should avoid exposure to minimize re-infection from environmental sources such as hot tubs, use of tap water in humidifiers and continuous positive airway pressure units, use of specialized filtration systems in household plumbing and exposure to soil and dust.

Surgical intervention

Surgery may be considered in carefully selected individuals with NTM-PD. These patients should have localized structural lung disease and good pulmonary functions without having impaired gas exchange[1],[17],[162]. The role of a pulmonary and/or infectious disease specialist, a respiratory therapist and a nutrition expert is crucial for a successful surgical outcome[186]. A review of retrospective anatomic lung resection for NTM-PD in 236 consecutive patients revealed minimal mortality and morbidity and reported that 80 per cent of patients had MAC-PD and had received DST-guided antibiotic treatment prior to surgery[187]. Data from the annual survey between 2008 and 2012 by the Japanese Association for Thoracic Surgery (JATS) have demonstrated a steady increase in the number of NTM surgeries[188]. In patients with extrapulmonary NTM disease, surgical intervention may be required through aggressive debridement or removal of implanted material[189]. Surgical excision is the treatment of choice in patients with solitary peripheral lymph node involvement due to NTM, especially in children[105],[106],[189].

Monitoring of drug toxicities

Drugs used for the treatment of NTM diseases are associated with several adverse events especially in elderly individuals and HIV/AIDS patients with multisystem involvement. During follow up, patients should be carefully monitored for side effects[1],[144],[190]. [Table 15] provides the details of adverse events and laboratory monitoring.


   Prevention Top


[Box 6] provides details of various preventive measures to reduce NTM disease in different settings, especially those due to contamination of disinfectants, ice, wounds, injection sites, catheters, endoscopes, etc., can be prevented by proper sterilization[2],[3]. Avoiding the use of tap water is considered a key step to prevent NTM infections in the hospital settings. Further, patients undergoing cardiac surgery and transplants should receive extra attention[10]. Besides different drug regimens, certain non-pharmacological options are available which can help in improving the quality of life in patients with NTM-PD. Chest physiotherapy can be helpful in improving lung functions and mucociliary clearance, especially in cavitary disease, CF and bronchiectasis. Breathing exercises including aerobic activity such as yoga are generally believed to be helpful in pulmonary rehabilitation[160]. Besides drug therapy, exposure to NTM, especially from household plumbing and water sources, should be avoided. NTM transmission can be prevented by increasing water temperature to ≥54°C (130°F) and changing shower heads regularly[10]. Patients with GERD should be advised to avoid foods that may trigger it and avoid vulnerable body positions that may cause repeated aspirations.

Patients should be advised to pay special attention to maintain adequate calorie intake and body mass index especially if surgical intervention is contemplated. Monitoring of pre-albumin level can serve as a useful marker of nutrition[184]. In some individuals along with antibiotic regimen, probiotic therapy can be helpful.

[Box 7] details recommendations for preventing disseminated MAC disease[19] and includes indications for initiating, discontinuing and restarting primary prophylaxis. Disseminated MAC disease must be carefully ruled out before starting drugs for primary prophylaxis. While azithromycin (1200 mg PO once weekly) or clarithromycin (500 mg PO twice daily) are preferred drugs, rifabutin (300 mg PO daily) is an alternative drug for primary prophylaxis provided that the active TB has been ruled out.




   Future prospects Top


Future studies should be directed to understand the role of risk factors for developing NTM-PD so that the benefit of screening can be offered to high risk individuals for early diagnosis and treatment. As growing evidence has established human-to-human transmission of M. abscessus among CF patients, further research should be done to study mechanisms contributing to patient-to-patient transmission of other NTM species to prevent further spread. Newer non-culture-based methods should be developed for early identification and speciation of NTM from respiratory specimens as the present methods rely heavily on mycobacterial culture for identification and further characterization of NTM species, causing significant delay in treatment. Future research should focus on understanding the role of DST in predicting treatment outcomes in NTM as currently the role of DST is controversial and limited only to a few situations in the management of NTM. Studies should also focus on understanding the pathogenic potential of various NTM species and subspecies to facilitate decision-making in treatment as there are significant knowledge gaps at present. Efforts should be made to follow progression of inflammatory lung disease systematically and to study treatment outcomes after timely intervention to develop and validate newer drugs and besides conventional routes of drug administration, potential use of drugs through inhalation route should be explored. Less toxic and more effective drug treatment regimens administered for short periods should be developed for the treatment of NTM-PD especially due to M. abscessus as these NTM species respond poorly to treatment with frequent relapses occurring after stopping the treatment.

Financial support & sponsorship: The first author (SKS) is sponsored by JC Bose Fellowship of the Science & Engineering Research Board (SERB No. SB/S2/ JCB-04/2013) of the Ministry of Science & Technology, Government of India. The second author (VU) is a Junior Research Fellow in the Department of Molecular Medicine at Jamia Hamdard University, Delhi, supported by

Dr SK Sharma through SERB JC Bose Fellowship.

Conflicts of Interest: None.



 
   References Top

1.
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respir Res 2017; 4 : e000242.   Back to cited text no. 1
    
2.
Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med 2015; 36 : 35-41.  Back to cited text no. 2
    
3.
Honda JR, Virdi R, Chan ED. Global environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches. Front Microbiol 2018; 9 : 2029.   Back to cited text no. 3
    
4.
Falkinham JO 3rd. Challenges of NTM drug development. Front Microbiol 2018; 9 : 1613.   Back to cited text no. 4
    
5.
Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am 1959; 43 : 273-90.  Back to cited text no. 5
    
6.
Cha SB, Jeon BY, Kim WS, Kim JS, Kim HM, Kwon KW, et al. Experimental reactivation of pulmonary Mycobacterium avium complex infection in a modified Cornell-like murine model. PLoS One 2015; 10 : e0139251.   Back to cited text no. 6
    
7.
Tortoli E, Fedrizzi T, Meehan CJ, Trovato A, Grottola A, Giacobazzi E, et al. The new phylogeny of the genus Mycobacterium: The old and the news. Infect Genet Evol 2017; 56 : 19-25.  Back to cited text no. 7
    
8.
Fedrizzi T, Meehan CJ, Grottola A, Giacobazzi E, Fregni Serpini G, Tagliazucchi S, et al. Genomic characterization of nontuberculous mycobacteria. Sci Rep 2017; 7 : 45258.  Back to cited text no. 8
    
9.
Parte AC. LPSN - List of Prokaryotic names with standing in Nomenclature (bacterio.net), 20 years on. Int J Syst Evol Microbiol 2018; 68 : 1825-9.  Back to cited text no. 9
    
10.
Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis 2019; 13 : e0007083.   Back to cited text no. 10
    
11.
Sarro YD, Kone B, Diarra B, Kumar A, Kodio O, Fofana DB, et al. Simultaneous diagnosis of tuberculous and non-tuberculous mycobacterial diseases: Time for a better patient management. Clin Microbiol Infect Dis 2018; 3 ; doi: 10.15761/CMID.1000144.  Back to cited text no. 11
    
12.
Filliol I, Driscoll JR, Van Soolingen D, Kreiswirth BN, Kremer K, Valétudie G, et al. Global distribution of Mycobacterium tuberculosis spoligotypes. Emerg Infect Dis 2002; 8 : 1347-9.  Back to cited text no. 12
    
13.
Bhalla GS, Sarao MS, Kalra D, Bandyopadhyay K, John AR. Methods of phenotypic identification of non-tuberculous mycobacteria. Pract Lab Med 2018; 12 : e00107.   Back to cited text no. 13
    
14.
Monteiro PHT, Martins MC, Ueki SYM, Giampaglia CMS, Telles MADS. Cord formation and colony morphology for the presumptive identification of Mycobacterium tuberculosis complex. Braz J Microbiol 2003; 34 : 171-4.   Back to cited text no. 14
    
15.
Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67 : 813-6.  Back to cited text no. 15
    
16.
Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes. 3rd ed. Wayne, PA: CLSI; 2018.  Back to cited text no. 16
    
17.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175 : 367-416.  Back to cited text no. 17
    
18.
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis 2020; 71 : 905-13.  Back to cited text no. 18
    
19.
Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf, accessed on May 18, 2020.   Back to cited text no. 19
    
20.
World Health Organization. WHO preferred product characteristics for new tuberculosis vaccines. Geneva: WHO; 2018.   Back to cited text no. 20
    
21.
Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science 2016; 354 : 751-7.  Back to cited text no. 21
    
22.
Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012; 185 : 881-6.  Back to cited text no. 22
    
23.
Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013; 42 : 1604-13.  Back to cited text no. 23
    
24.
Shao Y, Chen C, Song H, Li G, Liu Q, Li Y, et al. The epidemiology and geographic distribution of nontuberculous mycobacteria clinical isolates from sputum samples in the eastern region of China. PLoS Negl Trop Dis 2015; 9 : e0003623.  Back to cited text no. 24
    
25.
Thomson RM, NTM working group at Queensland TB Control Centre and Queensland Mycobacterial Reference Laboratory. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010; 16 : 1576-83.  Back to cited text no. 25
    
26.
Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010; 182 : 970-6.  Back to cited text no. 26
    
27.
Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review. Clin Chest Med 2015; 36 : 13-34.  Back to cited text no. 27
    
28.
Simons S, van Ingen J, Hsueh PR, Van Hung N, Dekhuijzen PN, Boeree MJ, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011; 17 : 343-9.  Back to cited text no. 28
    
29.
Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 2014; 11 : 1-8.  Back to cited text no. 29
    
30.
Lai CC, Tan CK, Chou CH, Hsu HL, Liao CH, Huang YT, et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis 2010; 16 : 294-6.  Back to cited text no. 30
    
31.
Jing H, Wang H, Wang Y, Deng Y, Li X, Liu Z, et al. Prevalence of nontuberculous mycobacteria infection, China, 2004-2009. Emerg Infect Dis 2012; 18 : 527-8.  Back to cited text no. 31
    
32.
Chou MP, Clements AC, Thomson RM. A spatial epidemiological analysis of nontuberculous mycobacterial infections in Queensland, Australia. BMC Infect Dis 2014; 14 : 279.   Back to cited text no. 32
    
33.
Koh WJ, Chang B, Jeong BH, Jeon K, Kim SY, Lee NY, et al. Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary Referral Hospital in South Korea. Tuberc Respir Dis(Seoul) 2013; 75 : 199-204.  Back to cited text no. 33
    
34.
Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: Incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181 : 514-21.  Back to cited text no. 34
    
35.
Shah NM, Davidson JA, Anderson LF, Lalor MK, Kim J, Thomas HL, et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect Dis 2016; 16 : 195.   Back to cited text no. 35
    
36.
Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 2013; 19 : 1889-91.  Back to cited text no. 36
    
37.
Adelman MH, Addrizzo-Harris DJ. Management of nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med 2018; 24 : 212-9.   Back to cited text no. 37
    
38.
Rivero-Lezcano OM, González-Cortés C, Mirsaeidi M. The unexplained increase of nontuberculous mycobacteriosis. Int J Mycobacteriol 2019; 8 : 1-6  Back to cited text no. 38
    
39.
Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacteria disease prevalence and risk factors: A changing epidemiology. Clin Infect Dis 2009; 49 : e124-9.  Back to cited text no. 39
    
40.
Zamarioli LA, Coelho AG, Pereira CM, Nascimento AC, Ueki SY, Chimara E. Descriptive study of the frequency of nontuberculous mycobacteria in the Baixada Santista region of the state of São Paulo, Brazil. J Bras Pneumol 2008; 34 : 590-4.  Back to cited text no. 40
    
41.
Kennedy MP, O'Connor TM, Ryan C, Sheehan S, Cryan B, Bredin C. Nontuberculous mycobacteria: Incidence in Southwest Ireland from 1987 to 2000. Respir Med 2003; 97 : 257-63.  Back to cited text no. 41
    
42.
McCallum AD, Watkin SW, Faccenda JF. Non-tuberculous mycobacterial infections in the Scottish Borders: Identification, management and treatment outcomes - a retrospective review. J R Coll Physicians Edin 2011; 41 : 294-303  Back to cited text no. 42
    
43.
Moore JE, Kruijshaar ME, Ormerod LP. Increasing reports of nontuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health 2010; 10 : 612.   Back to cited text no. 43
    
44.
van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009; 64 : 502-6.  Back to cited text no. 44
    
45.
Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C, Lozniewski A, et al. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J 2006; 28 : 1211-5.  Back to cited text no. 45
    
46.
Gerogianni I, Papala M, Kostikas K, Petinaki E, Gourgoulianis KI. Epidemiology and clinical significance of mycobacterial respiratory infections in Central Greece. Int J Tuberc Lung Dis 2008; 12 : 807-12.  Back to cited text no. 46
    
47.
Jankovic M, Samarzija M, Sabol I, Jakopovic M, Katalinic Jankovic V, Zmak L, et al. Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. Int J Tuberc Lung Dis 2013; 17 : 836-41.  Back to cited text no. 47
    
48.
Haverkort F. National atypical mycobacteria survey, 2000. Commun Dis Intell Q Rep 2003; 27 : 180-9.  Back to cited text no. 48
    
49.
Freeman J, Morris A, Blackmore T, Hammer D, Munroe S, McKnight L. Incidence of nontuberculous mycobacterial disease in New Zealand, 2004. N Z Med J 2007; 120 : U2580.  Back to cited text no. 49
    
50.
Nyamogoba HD, Mbuthia G, Mining S, Kikuvi G, Biegon R, Mpoke S, et al. HIV co-infection with tuberculous and non-tuberculous mycobacteria in western Kenya: Challenges in the diagnosis and management. Afr Health Sci 2012; 12 : 305-11.  Back to cited text no. 50
    
51.
Aliyu G, El-Kamary SS, Abimiku A, Brown C, Tracy K, Hungerford L, et al. Prevalence of non-tuberculous mycobacterial infections among tuberculosis suspects in Nigeria. PLoS One 2013; 8 : e63170  Back to cited text no. 51
    
52.
Asiimwe BB, Bagyenzi GB, Ssengooba W, Mumbowa F, Mboowa G, Wajja A, et al. Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda. BMC Infect Dis 2013; 13 : 88.  Back to cited text no. 52
    
53.
Badoum G, Saleri N, Dembélé MS, Ouedraogo M, Pinsi G, Boncoungou K, et al. Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Eur Respir J 2011; 37 : 1283-5.  Back to cited text no. 53
    
54.
Lee H, Myung W, Koh WJ, Moon SM, Jhun BW. Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007-2016. Emerg Infect Dis 2019; 25 : 569-72.   Back to cited text no. 54
    
55.
Yu X, Liu P, Liu G, Zhao L, Hu Y, Wei G, et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis. J Infect 2016; 73 : 558-67.  Back to cited text no. 55
    
56.
Lim AYH, Chotirmall SH, Fok ETK, Verma A, De PP, Goh SK, et al. Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore. BMC Pulm Med 2018; 18 : 85.  Back to cited text no. 56
    
57.
Nasiri MJ, Dabiri H, Fooladi AAI, Amini S, Hamzehloo G, Feizabadi MM. High rates of nontuberculous mycobacteria isolation from patients with presumptive tuberculosis in Iran. New Microbes New Infect 2017; 21 : 12-7.  Back to cited text no. 57
    
58.
Davari M, Irandoost M, Sakhaee F, Vaziri F, Sepahi AA, Rahimi Jamnani F, et al. Genetic diversity and prevalence of nontuberculous mycobacteria isolated from clinical samples in Tehran, Iran. Microb Drug Resist 2019; 25 : 264-70.  Back to cited text no. 58
    
59.
Myneedu VP, Verma AK, Bhalla M, Arora J, Reza S, Sah GC, et al. Occurrence of non-tuberculous Mycobacterium in clinical samples - a potential pathogen. Indian J Tuberc 2013; 60 : 71-6.  Back to cited text no. 59
    
60.
Jain S, Sankar MM, Sharma N, Singh S, Chugh TD. High prevalence of non-tuberculous mycobacterial disease among non-HIV infected individuals in a TB endemic country - experience from a tertiary center in Delhi, India. Pathog Glob Health 2014; 108 : 118-22.  Back to cited text no. 60
    
61.
Sharma SK, Sharma R, Singh BK, Upadhyay V, Mani I, Tripathi M, et al. A prospective study of non-tuberculous mycobacterial disease among tuberculosis suspects at a tertiary care centre in north India. Indian J Med Res 2019; 150 : 458-67.  Back to cited text no. 61
    
62.
Paramasivan CN, Govindan D, Prabhakar R, Somasundaram PR, Subbammal S, Tripathy SP. Species level identification of non-tuberculous mycobacteria from South Indian BCG trial area during 1981. Tubercle 1985; 66 : 9-15.  Back to cited text no. 62
    
63.
Goswami B, Narang P, Mishra PS, Narang R, Narang U, Mendiratta DK. Drug susceptibility of rapid and slow growing non-tuberculous mycobacteria isolated from symptomatics for pulmonary tuberculosis, Central India. Indian J Med Microbiol 2016; 34 : 442-7.  Back to cited text no. 63
    
64.
Maurya AK, Nag VL, Kant S, Kushwaha RA, Kumar M, Singh AK, et al. Prevalence of nontuberculous mycobacteria among extrapulmonary tuberculosis cases in tertiary care centers in Northern India. Biomed Res Int 2015; 2015 : 465403.  Back to cited text no. 64
    
65.
Umrao J, Singh D, Zia A, Saxena S, Sarsaiya S, Singh S, et al. Prevalence and species spectrum of both pulmonary and extrapulmonary nontuberculous mycobacteria isolates at a tertiary care center. Int J Mycobacteriol 2016; 5 : 288-93.  Back to cited text no. 65
    
66.
Sairam B, Gogia A, Kakar A, Byotra SP. 781. Non-tuberculous mycobacterium: often a missed entity. Open Forum Infect Dis 2018; 5 (Suppl 1) : S280.   Back to cited text no. 66
    
67.
Jesudason MV, Gladstone P. Non tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital in South India. Indian J Med Microbiol 2005; 23 : 172-5.  Back to cited text no. 67
    
68.
Sivasankari P, Khyriem AB, Venkatesh K, Parija SC. Atypical mycobacterial infection among HIV seronegative patients in Pondicherry. Indian J Chest Dis Allied Sci 2006; 48 : 107-9.  Back to cited text no. 68
    
69.
Radha Bai Prabhu T, Pandiyan N, Sujatha N, Jawahar MS. Significance of isolating non-tuberculous mycobacterial organisms in infertile women with tubal disease: An observational study. BJOG 2019; 126 (Suppl 4) : 66-71.  Back to cited text no. 69
    
70.
Narang P, Narang R, Mendiratta DK, Roy D, Deotale V, Yakrus MA, et al. Isolation of Mycobacterium avium complex and M. simiae from blood of AIDS patients from Sevagram, Maharashtra. Indian J Tuberc 2005; 52 : 21-6.  Back to cited text no. 70
    
71.
Shenai S, Rodrigues C, Mehta A. Time to identify and define non-tuberculous mycobacteria in a tuberculosis-endemic region. Int J Tuberc Lung Dis 2010; 14 : 1001-8.  Back to cited text no. 71
    
72.
Adjemian J, Olivier KN, Seitz AE, Falkinham JO 3rd, Holland SM, Prevots DR. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012; 186 : 553-8.  Back to cited text no. 72
    
73.
Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis 2015; 15 : 968-80.  Back to cited text no. 73
    
74.
Jeon D. Infection source and epidemiology of nontuberculous mycobacterial lung disease. Tuberc Respir Dis (Seoul) 2019; 82 : 94-101.  Back to cited text no. 74
    
75.
Fowler CJ, Olivier KN, Leung JM, Smith CC, Huth AG, Root H, et al. Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med 2013; 187 : 1374-81.  Back to cited text no. 75
    
76.
Jang MA, Kim SY, Jeong BH, Park HY, Jeon K, Kim JW, et al. Association of CFTR gene variants with nontuberculous mycobacterial lung disease in a Korean population with a low prevalence of cystic fibrosis. J Hum Genet 2013; 58 : 298-303.  Back to cited text no. 76
    
77.
Kalayjian RC, Toossi Z, Tomashefski JF Jr, Carey JT, Ross JA, Tomford JW, et al. Pulmonary disease due to infection by Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1995; 20 : 1186-94.  Back to cited text no. 77
    
78.
Reich JM. In Defense of Lady Windermere Syndrome. Lung 2018; 196 : 377-9.  Back to cited text no. 78
    
79.
Kumfer AM, Edriss H. Lady Windermere Syndrome. The Chronicles 2017; 5 : 22-32.  Back to cited text no. 79
    
80.
Reich JM. Cough suppression disorders spectrum. Respir Med 2014; 108 : 413-5.  Back to cited text no. 80
    
81.
Koh WJ, Lee JH, Kwon YS, Lee KS, Suh GY, et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest 2007; 131 : 1825-30.  Back to cited text no. 81
    
82.
Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007; 13 : 1166-72.  Back to cited text no. 82
    
83.
Chan ED, Iseman MD. Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease. Gend Med 2010; 7 : 5-18.  Back to cited text no. 83
    
84.
Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis 2016; 45 : 123-34.  Back to cited text no. 84
    
85.
Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax 2007; 62 : 661-6.  Back to cited text no. 85
    
86.
O'Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis 1987; 135 : 1007-14.  Back to cited text no. 86
    
87.
van Ingen J, Boeree MJ, de Lange WC, Hoefsloot W, Bendien SA, Magis-Escurra C, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008; 14 : 385-9.  Back to cited text no. 87
    
88.
van Ingen J, de Zwaan R, Dekhuijzen RP, Boeree MJ, van Soolingen D. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009; 59 : 324-31.  Back to cited text no. 88
    
89.
van Ingen J, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis 2010; 14 : 1176-80.  Back to cited text no. 89
    
90.
Hoefsloot W, Boeree MJ, van Ingen J, Bendien S, Magis C, de Lange W, et al. The rising incidence and clinical relevance of Mycobacterium malmoense: A review of the literature. Int J Tuberc Lung Dis 2008; 12 : 987-93.  Back to cited text no. 90
    
91.
Wallace Jr RJ, Zhang Y, Brown BA, Dawson D, Murphy DT, Wilson R, et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998; 158 : 1235-44.  Back to cited text no. 91
    
92.
Lim H-J, Park CM, Park YS, Lee J, Lee S-M, Yang S-C, et al. Isolation of multiple nontuberculous mycobacteria species in the same patients. Int J Infect Dis 2011; 15 : e795–8.  Back to cited text no. 92
    
93.
Wallace RJ Jr, Zhang Y, Brown-Elliott BA, Yakrus MA, Wilson RW, Mann L, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002; 186 : 266-73.  Back to cited text no. 93
    
94.
Nishiuchi Y, Iwamoto T, Maruyama F. Infection Sources of a common non-tuberculous mycobacterial pathogen, Mycobacterium avium Complex. Front Med (Lausanne) 2017; 4 : 27.   Back to cited text no. 94
    
95.
Boyle DP, Zembower TR, Reddy S, Qi C. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med 2015; 191 : 1310-7.  Back to cited text no. 95
    
96.
Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J 2017; 49 : 1600537.  Back to cited text no. 96
    
97.
Horne D, Skerrett S. Recent advances in nontuberculous mycobacterial lung infections. F1000Res 2019; 8 : F1000 Faculty Rev-1710.  Back to cited text no. 97
    
98.
Wassilew N, Hoffmann H, Andrejak C, Lange C. Pulmonary disease caused by non-tuberculous mycobacteria. Respiration 2016; 91 : 386-402.  Back to cited text no. 98
    
99.
Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147 : 1271-8.   Back to cited text no. 99
    
100.
Koh WJ, Stout JE, Yew WW. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Int J Tuberc Lung Dis 2014; 18 : 1141-8.  Back to cited text no. 100
    
101.
Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: Clinicians' perspectives. Tuberc Respir Dis (Seoul) 2016; 79 : 74-84.  Back to cited text no. 101
    
102.
Fjällbrant H, Akerstrom M, Svensson E, Andersson E. Hot tub lung: an occupational hazard. Eur Respir Rev 2013; 22 : 88-90.  Back to cited text no. 102
    
103.
Larsson LO, Polverino E, Hoefsloot W, Codecasa LR, Diel R, Jenkins SG, et al. Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives. Expert Rev Respir Med 2017; 11 : 977-89.  Back to cited text no. 103
    
104.
Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis 2014; 6 : 210-20.  Back to cited text no. 104
    
105.
Bhattacharya J, Mohandas S, Goldman DL. Nontuberculous mycobacterial infections in children. Pediatr Rev 2019; 40 : 179-90.  Back to cited text no. 105
    
106.
Deveci HS, Kule M, Kule ZA, Habesoglu TE. Diagnostic challenges in cervical tuberculous lymphadenitis: A review. North Clin Istanb 2016; 3 : 150-5.  Back to cited text no. 106
    
107.
Portaels F, Silva MT, Meyers WM. Buruli Ulcer. Clin Dermatol 2009; 27 : 291-305.  Back to cited text no. 107
    
108.
Deshayes C, Angala SK, Marion E, Brandli I, Babonneau J, Preisser L, et al. Regulation of mycolactone, the Mycobacterium ulcerans toxin, depends on nutrient source. PLoS Negl Trop Dis 2013; 7 : e2502.  Back to cited text no. 108
    
109.
Sakyi SA, Kennedy MP, Aboagye SY, Darko Otchere I, Yeboah-Manu D. Clinical and laboratory diagnosis of Buruli ulcer disease: A systematic review. Can J Infect Dis Med Microbiol 2016; 2016 : 5310718.  Back to cited text no. 109
    
110.
Petrini B. Mycobacterium marinum: Ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis 2006; 25 : 609-13.  Back to cited text no. 110
    
111.
Hashish E, Merwad A, Elgaml S, Amer A, Kamal H, Elsadek A, et al. Mycobacterium marinum infection in fish and man: Epidemiology, pathophysiology and management; a review. Vet Q 2018; 38 : 35-46.  Back to cited text no. 111
    
112.
Tirado-Sánchez A, Bonifaz A. Nodular lymphangitis (sporotrichoid lymphocutaneous infections). Clues to differential diagnosis. J Fungi(Basel) 2018; 4 : 56.  Back to cited text no. 112
    
113.
Uslan DZ, Kowalski TJ, Wengenack NL, Virk A, Wilson JW. Skin and soft tissue infections due to rapidly growing mycobacteria: Comparison of clinical features, treatment, and susceptibility. Arch Dermatol 2006; 142 : 1287-92.  Back to cited text no. 113
    
114.
Misch EA, Saddler C, Davis JM. Skin and soft tissue infections due to nontuberculous mycobacteria. Curr Infect Dis Rep 2018; 20 : 6.  Back to cited text no. 114
    
115.
Xu X, Lao X, Zhang C, Cao C, Ding H, Pang Y, et al. Mycobacterium avium skin and soft tissue infection complicated with scalp osteomyelitis possibly secondary to anti-interferon-γ autoantibody formation. BMC Infect Dis 2019; 19 : 203.   Back to cited text no. 115
    
116.
Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 2009; 15 : 1351-8; quiz 1544.   Back to cited text no. 116
    
117.
Bauer J, Andersen AB, Askgaard D, Giese SB, Larsen B. Typing of clinical Mycobacterium avium complex strains cultured during a 2-year period in Denmark by using IS1245. J Clin Microbiol 1999; 37 : 600-5.  Back to cited text no. 117
    
118.
MacDonell KB, Glassroth J. Mycobacterium avium complex and other nontuberculous mycobacteria in patients with HIV infection. Semin Respir Infect 1989; 4 : 123-32.   Back to cited text no. 118
    
119.
Damsker B, Bottone EJ. Mycobacterium avium-Mycobacterium intracellulare from the intestinal tracts of patients with the acquired immunodeficiency syndrome: concepts regarding acquisition and pathogenesis. J Infect Dis 1985; 151 : 179-81.  Back to cited text no. 119
    
120.
Hill AR. Mycobacterial infections in AIDS. Can J Infect Dis 1991; 2 : 19-29.  Back to cited text no. 120
    
121.
Gupta-Wright A, Kerkhoff AD, Meintjes G, Corbett EL. Urinary lipoarabinomannan detection and disseminated nontuberculous mycobacterial disease. Clin Infect Dis 2018; 66 : 158.   Back to cited text no. 121
    
122.
Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med 2015; 36 : 91-9.  Back to cited text no. 122
    
123.
Chalermskulrat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera MP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61 : 507-13.  Back to cited text no. 123
    
124.
Blanc P, DSutronc H, Peuchant O, Dauchy FA, Cazanave C, Neau D, et al. Nontuberculous mycobacterial infections in a French Hospital: A 12-year retrospective study. PLoS One 2016; 11 : e0168290.   Back to cited text no. 124
    
125.
Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72 : 37-42.   Back to cited text no. 125
    
126.
Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood 2012; 119 : 3933-9.  Back to cited text no. 126
    
127.
Yeh YK, Ding JY, Ku CL, Chen WC. Disseminated Mycobacterium avium complex infection mimicking malignancy in a patient with anti-IFN-γ autoantibodies: A case report. BMC Infect Dis 2019; 19 : 909.   Back to cited text no. 127
    
128.
Orduña P, Castillo-Rodal AI, Mercado ME, Ponce de León S, López-Vidal Y. Specific proteins in nontuberculous mycobacteria: New potential tools. Biomed Res Int 2015; 2015 : 964178.  Back to cited text no. 128
    
129.
Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol 2020; 18 : 392-407.   Back to cited text no. 129
    
130.
Forbes BA, Hall GS, Miller MB, Novak SM, Rowlinson MC, Salfinger M, et al. Practice guidelines for clinical microbiology laboratories: Mycobacteria. Clin Microbiol Rev 2018; 31 : e00038-17.  Back to cited text no. 130
    
131.
Stephenson D, Perry A, Appleby MR, Lee D, Davison J, Johnston A, et al. An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation. BMC Pulm Med 2019; 19 : 19.   Back to cited text no. 131
    
132.
Palmore TN, Shea YR, Conville PS, Witebsky FG, Anderson VL, Rupp Hodge IP, et al. “Mycobacterium tilburgii,” a newly described, uncultivated opportunistic pathogen. J Clin Microbiol 2009; 47 : 1585-7.  Back to cited text no. 132
    
133.
Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev 2014; 27 : 727-52.  Back to cited text no. 133
    
134.
Kwon YS, Daley CL, Koh WJ. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: Challenges and new approaches. Expert Rev Respir Med 2019; 13 : 851-61.  Back to cited text no. 134
    
135.
Matsumoto Y, Kinjo T, Motooka D, Nabeya D, Jung N, Uechi K, et al. Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles. Emerg Microbes Infect 2019; 8 : 1043-53.  Back to cited text no. 135
    
136.
Quan TP, Bawa Z, Foster D, Walker T, Del Ojo Elias C Rathod P, et al. Evaluation of whole-genome sequencing for mycobacterial species identification and drug susceptibility testing in a clinical setting: a large-scale prospective assessment of performance against line probe assays and phenotyping. J Clin Microbiol 2018; 56 : e01480-17.  Back to cited text no. 136
    
137.
Mediavilla-Gradolph MC, De Toro-Peinado I, Bermúdez-Ruiz MP, García-MartínezMde L, Ortega-Torres M, Quezel-Guerraz NM, et al. Use of MALDI-TOF MS for identification of nontuberculous mycobacterium species isolated from clinical specimens. Biomed Res Int 2015; 2015 : 854078.   Back to cited text no. 137
    
138.
Kehrmann J, Schoerding AK, Murali R, Wessel S, Koehling HL, Mosel F, et al. Performance of Vitek MS in identifying nontuberculous mycobacteria from MGIT liquid medium and Lowenstein-Jensen solid medium. Diagn Microbiol Infect Dis 2016; 84 : 43-7.  Back to cited text no. 138
    
139.
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71 (Suppl 1) : i1-22.   Back to cited text no. 139
    
140.
Jhun BW, Yang B, Moon SM, Lee H, Park HY, Jeon K, et al. Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease. Antimicrob Agents Chemother 2018; 62. pii: e00011-18.   Back to cited text no. 140
    
141.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med 2018; 198 : 1559-69.  Back to cited text no. 141
    
142.
Pan SW, Shu CC, Feng JY, Wang JY, Chan YJ, Yu CJ, et al. Microbiological persistence in patients with Mycobacterium avium complex lung disease: The predictors and the impact on radiographic progression. Clin Infect Dis 2017; 65 : 927-34.   Back to cited text no. 142
    
143.
Kim SJ, Park J, Lee H, Lee YJ, Park JS, Cho YJ, et al. Risk factors for deterioration of nodular bronchiectatic Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis 2014; 18 : 730-6.   Back to cited text no. 143
    
144.
Shulha JA, Escalante P, Wilson JW. Pharmacotherapy Approaches in Nontuberculous Mycobacteria Infections. Mayo Clin Proc 2019; 94 : 1567-81.  Back to cited text no. 144
    
145.
Balavoine C, Blanc FX, Lanotte P, Meurice JC, Andrejak C, Marchand-Adam S. Adverse events during treatment of nontuberculous mycobacterial lung disease: Do they really matter? Eur Respir J 2018; 52 : PA2664.  Back to cited text no. 145
    
146.
Griffith D. Treatment of Mycobacterium avium complex (MAC). Semin Respir Crit Care Med 2018; 39 : 351-61.   Back to cited text no. 146
    
147.
Strnad L, Winthrop KL. Treatment of Mycobacterium abscessus complex. Semin Respir Crit Care Med 2018; 39 : 362-76.   Back to cited text no. 147
    
148.
Basille D, Jounieaux V. Treatment of other nontuberculous mycobacteria. Semin Respir Crit Care Med 2018; 39 : 377-82   Back to cited text no. 148
    
149.
van Ingen J, Boeree M, van Soolingen D, and Mouton J. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15 : 149-61.  Back to cited text no. 149
    
150.
Kim HJ, Lee JS, Kwak N, Cho J, Lee CH, Han SK, et al. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease. BMC Pulm Med 2019; 19 : 212.   Back to cited text no. 150
    
151.
Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174 : 928-34.  Back to cited text no. 151
    
152.
Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2015; 191 : 96-103.   Back to cited text no. 152
    
153.
Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004; 126 : 566-81.   Back to cited text no. 153
    
154.
Xu HB, Jiang RH, Li L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2014; 33 : 347-58.  Back to cited text no. 154
    
155.
Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis 2017; 65 : 1077-84.  Back to cited text no. 155
    
156.
Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. J Antimicrob Chemother 2017; 72 (Supp 2) : i3-19.   Back to cited text no. 156
    
157.
Diel R, Nienhaus A, Ringshausen FC, Richter E, Welte T, Rabe KF, et al. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: A systematic review. Chest 2018; 153 : 888-921.  Back to cited text no. 157
    
158.
Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc 2014; 11 : 23-9.  Back to cited text no. 158
    
159.
Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J 2017; 50. pii: 1602503.   Back to cited text no. 159
    
160.
Moon SM, Park HY, Kim SY, Jhun BW, Lee H, Jeon K, et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother 2016; 60 : 6758-65.  Back to cited text no. 160
    
161.
Morimoto K, Namkoong H, Hasegawa N, Nakagawa T, Morino E, Shiraishi Y, et al. Macrolide-resistant Mycobacterium avium complex lung disease: Analysis of 102 consecutive cases. Ann Am Thorac Soc 2016; 13 : 1904-11.  Back to cited text no. 161
    
162.
Park Y, Lee EH, Jung I, Park G, Kang YA. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: A systematic review and meta-analysis. Respir Res 2019; 20 : 286.  Back to cited text no. 162
    
163.
DeStefano MS, Shoen CM, Cynamon MH. Therapy for Mycobacterium kansasii infection: Beyond 2018. Front Microbiol 2018; 9 : 2271.   Back to cited text no. 163
    
164.
Sun Z, Zhang Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother 1999; 43 : 537-42.  Back to cited text no. 164
    
165.
Zaheen A, Hirama T, Mehrabi M, Brode SK, Marras TK. Clinical outcomes in Mycobacterium xenopi versus Mycobacterium avium complex pulmonary disease: A retrospective matched cohort study. Respir Med 2020; 167 : 105967.  Back to cited text no. 165
    
166.
van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012; 39 : 173-6.  Back to cited text no. 166
    
167.
van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012; 56 : 6324-7.  Back to cited text no. 167
    
168.
Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis 2017; 64 : 309-16.  Back to cited text no. 168
    
169.
Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother 2017; 61. pii: e01206-17.   Back to cited text no. 169
    
170.
Okamori S, Asakura T, Nishimura T, Tamizu E, Ishii M, Yoshida M, et al. Natural history of Mycobacterium fortuitum pulmonary infection presenting with migratory infiltrates: A case report with microbiological analysis. BMC Infect Dis 2018; 18 : 1.   Back to cited text no. 170
    
171.
Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Lindeboom R, Prins JM. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 44 : 1057-64.  Back to cited text no. 171
    
172.
Aubry A, Chosidow O, Caumes E, Robert J Cambau E. Sixty-three cases of Mycobacterium marinum infection: Clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162 : 1746-52.  Back to cited text no. 172
    
173.
Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Expert Opin Pharmacother 2007; 8 : 2965-78.  Back to cited text no. 173
    
174.
Lewis FM, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis 2003; 37 : 390-7.  Back to cited text no. 174
    
175.
Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, et al. Oral treatment for Mycobacterium ulcerans infection: Results from a pilot study in Benin. Clin Infect Dis 2011; 52 : 94-6  Back to cited text no. 175
    
176.
O'Brien DP, McDonald A, Callan P, Robson M, Friedman ND, Hughes A, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: An observational cohort study. PLoS Negl Trop Dis 2012; 6 : e1473.   Back to cited text no. 176
    
177.
Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119 : 482-6.  Back to cited text no. 177
    
178.
Wallace RJ, Swenson JM, Silcox VA, Bulen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonae on the basis of in vitro susceptibilities. J Infect Dis 1985; 152 : 500-14.  Back to cited text no. 178
    
179.
Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, et al. Macrolide/Azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 2014; 146 : 276-82.  Back to cited text no. 179
    
180.
Banaschewski B, Verma D, Pennings LJ, Zimmerman M, Ye Q, Gadawa J, et al. Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections. J Cyst Fibros 2019; 18 : 714-20.  Back to cited text no. 180
    
181.
Yagi K, Ishii M, Namkoong H, Asami T, Iketani O, Asakura T, et al. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infect Dis 2017; 17 : 558.   Back to cited text no. 181
    
182.
Olivier KN, Shaw PA, Glaser TS, Bhattacharyya D, Fleshner M, Brewer CC, et.al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014; 11 : 30-5.   Back to cited text no. 182
    
183.
Yaacoby-Bianu K, Gur M, Toukan Y, Nir V, Hakim F, Geffen Y, et al. Compassionate nitric oxide adjuvant treatment of persistent Mycobacterium infection in cystic fibrosis patients. Pediatr Infect Dis J 2018; 37 : 336-8.  Back to cited text no. 183
    
184.
Basavaraj A, Segal L, Samuels J, Feintuch J, Feintuch J, Alter K, et al. Effects of chest physical therapy in patients with non-tuberculous mycobacteria. Int J Respir Pulm Med 2017; 4. pii: 065.   Back to cited text no. 184
    
185.
Wakamatsu K, Nagata N, Maki S, Omori H, Kumazoe H, Ueno K, et al. Patients with MAC lung disease have a low visceral fat area and low nutrient intake. Pulm Med 2015; 2015 : 218253.   Back to cited text no. 185
    
186.
Lu M, Fitzgerald D, Karpelowsky J, Selvadurai H, Pandit C, Robinson P, et al. Surgery in nontuberculous mycobacteria pulmonary disease. Breathe (Sheff) 2018; 14 : 288-301.  Back to cited text no. 186
    
187.
Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Marvin P. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg 2008; 85 : 1887-93.  Back to cited text no. 187
    
188.
Shiraishi, Y. Current status of nontuberculous mycobacterial surgery in Japan: Analysis of data from the annual survey by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2016; 64 :14-7.   Back to cited text no. 188
    
189.
Wi YM. Treatment of extrapulmonary nontuberculous mycobacterial diseases. Infect Chemother 2019; 51 : 245-55.  Back to cited text no. 189
    
190.
Schlossberg D, editor. Nontuberculous mycobacteria -Overview. In: Tuberculosis and nontuberculous mycobacterial infections. 7th ed. Washington, DC: ASM Press; 2017. p. 655-61.  Back to cited text no. 190
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8], [Table 9], [Table 10], [Table 11], [Table 12], [Table 13], [Table 14], [Table 15], [Table 16]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Epidemiology
    Clinical manifes...
   Diagnosis
    Treatment of NTM...
   Prevention
   Future prospects
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed363    
    Printed0    
    Emailed0    
    PDF Downloaded125    
    Comments [Add]    

Recommend this journal